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Introduction
Staphylococcus aureus is the most common causative
agent of septic arthritis [1–3], a severe, rapidly progress-
ing, erosive disease with high morbidity and mortality.
Inflammatory processes during septic arthritis erode artic-
ular cartilage, destroy bone and promote joint destruction
leading to irreversible loss of joint function in 25–50% of
patients [4,5]. Early administration of antibiotics eradicates
the bacteria, but does not stop joint destruction. We have
previously shown that antibacterial therapy combined with
systemic corticosteroid administration ameliorated S.
aureus arthritis in mice [6]. The compound α-phenyl-N-
tert-butyl nitrone (PBN) was originally developed as a
means of trapping and detecting free radical intermediates
[7]. PBN and related nitrones have a variety of anti-inflam-
matory and antioxidant properties. Therefore we consid-
ered whether PBN might be an effective therapeutic in
septic arthritis. In this study, we evaluated the efficacy of a
combined PBN and antibiotic (cloxacillin) treatment in
reducing joint destruction during staphylococcal arthritis in
a murine model of hematogenously spread S. aureus
sepsis and septic arthritis [8,9].
Materials and methods
The arthritis model
Female 5–8 week-old Naval Medical Research Institute
(NMRI) mice were injected intravenously in the tail vein
with an arthritogenic dose of S. aureus LS-1 [6]. Limbs
were inspected (by a blinded observer) at various time-
points after bacterial inoculation. A system of clinical
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scoring (arthritic index; 0–3 scale) was used to assess the
severity of arthritis in each limb [10]. The total index was
calculated by adding the individual limb scores for each
animal tested. The cure rate was estimated by subtracting
the arthritic index at day 10 (i.e. seven days after treatment
commencement) from that at day three (i.e. just prior to
treatment commencement).
Histopathological examination
The animals were sacrificed ten days after inoculation of
bacteria and the joints were examined histologically [6] for
synovial hypertrophy (synovial membrane thickness of
more than two cell layers [11]), pannus formation and
destruction of cartilage and subchondral bone. To evalu-
ate the severity of synovitis and cartilage and/or bone
destruction, a histological scoring system (histological
index) was employed [12]. The total histological index was
calculated by totaling all the scores for each animal tested.
Bacteriological examination
After sacrifice, kidneys were aseptically removed, homoge-
nized manually at 4°C, diluted in PBS, and inoculated on
horse blood agar in serial dilutions to estimate the bacter-
ial load in each organ.
Treatment procedures
Cloxacillin (Astra, Södertälje, Sweden) was dissolved in
sterile PBS, and mice were injected intraperitoneally with
0.1 ml of the solution, corresponding to 500 mg/kg body
weight, every 12 hours, starting on day three after inocula-
tion of bacteria and continuing until the animals were sac-
rificed.
Phenyl-N-tert-butyl nitrone (PBN) (Sigma, St Louis, MO,
USA) was diluted in 0.1 ml of sterile PBS and injected
intraperitoneally (40 mg/kg body weight) every 12 hours,
starting on day zero or day three after inoculation of bacte-
ria and continuing until the animals were sacrificed. PBN
is not bactericidal for S. aureus.
Statistical analyses
The differences between parametric and nonparametric
values in all treatment groups were tested for significance
by use of the two-tailed Student’s t-test and the Mann-
Whitney U-test, respectively. Differences between groups
in the incidence of arthritis and mortality were analyzed by
the Fisher’s exact test. Results are presented as the
mean ± SEM. A P value of less than 0.05 was considered
statistically significant.
Results
The effect of PBN-alone treatment on sepsis and septic
arthritis
The treatment with PBN alone started on day zero, and
had no effect either on the prevalence or severity of arthri-
tis. Thus, 21 days after the treatment was started, six out
of nine mice in the control group, and four out of seven in
the PBN-treated group exhibited symptoms of arthritis
The mean arthritic index was 1.7 ± 0.1 in both groups.
However, we observed a moderate increase in the mortal-
ity rate in the PBN-treated animals; 30% of the PBN-
treated animals died, compared to 10% of control
animals (n = 10 per group) by day 21 postinfection (data
not shown).
The effect of combined PBN-cloxacillin treatment on
the clinical course of sepsis and septic arthritis
In order to evaluate the effect of combined PBN-cloxacillin
treatment, forty 5–6-week-old female NMRI mice were
injected intravenously with arthritogenic doses of
S. aureus LS-1. The mice were subdivided into four
groups and treatment began three days after infection.
The first (control) group was given no treatment, the
second group was treated with cloxacillin alone, the third
group was given PBN plus cloxacillin, and the fourth group
received PBN only. The experiment was performed three
times. The fourth group was excluded in the last experi-
ment. Since all three experiments displayed similar out-
comes, the clinical, bacteriologic and histologic results
were pooled.
Three days after inoculation of bacteria, 56–70% of all
groups had developed symptoms of arthritis. The fre-
quency and severity of arthritis are depicted in Fig. 1. On
day 10 after inoculation of bacteria (seven days after treat-
ment was initiated), the frequency and severity of arthritis
increased in all the groups, except for the group receiving
combined treatment. Thus, 59% of mice receiving com-
bined treatment exhibited symptoms of arthritis, compared
to 64% in the cloxacillin-alone treated group and 70% in
the controls. The prevalence of arthritis was greatest in the
PBN-alone treated mice (74%). The severity of arthritis fol-
lowed a similar pattern: mean arthritic index in mice receiv-
ing combined treatment was 0.9 ± 0.2, compared to
1.1 ± 0.2 in the cloxacillin-alone treated group, 1.6 ± 0.3
in the controls and 2.0 ± 0.4 in PBN-alone treated
animals. Mice receiving combined PBN-cloxacillin treat-
ment exhibited significantly improved cure rates compared
to groups receiving treatments with either PBN alone
(P < 0.05), cloxacillin alone (P < 0.05), or untreated con-
trols (P < 0.01) (Fig. 2).
Histopathological findings
The frequency of synovitis was 85–90% in all treatment
groups. Fifty-five percent of mice receiving the PBN-
cloxacillin treatment displayed cartilage destruction, com-
pared to 70% in the cloxacillin-alone and PBN-alone
groups and 74% in the control group. The severity of his-
tological changes was lowest in the animals receiving
combined treatment (Fig. 3).Arthritis Research    Vol 4 No 3 Sakiniene and Collins
Bacteriological findings
All of the control and PBN-alone treated mice harbored
bacteria in the kidneys 10 days after infection, compared
to 58% of mice treated with combined PBN-cloxacillin
therapy, and 68% of mice treated with cloxacillin alone.
The numbers of bacteria in kidneys were significantly
lower in the combined PBN-cloxacillin and cloxacillin-alone
groups than in the control or PBN-alone treatment groups
(Fig. 4).
Discussion
We used a murine model of hematogenously acquired
S. aureus arthritis to evaluate the effects of PBN treatment,
given alone or in combination with cloxacillin. Treatment
efficacy was expressed as the cure rate (i.e. arthritic index
changes following treatment of infected mice). The com-
bined PBN-cloxacillin treatment significantly (P < 0.05)
increased the cure rate, compared to cloxacillin-alone treat-
ment. Histological investigation confirmed these results.
Joint destruction develops early (within 48 hours) in S.
aureus infection [12,13]. Therefore, the occurrence, even
in the treated animals, of erosions is not surprising, bearing
in mind that the treatment was started three days after
inoculation of bacteria. This was done in an attempt to
reflect the clinical situation when patients present with
staphylococcal infections. It is important to note that
despite the higher prevalence and severity of arthritis at the
start of the treatment modalities, the joints of mice receiv-
ing combined treatment exhibited less severe histological
changes. Therefore, PBN appears to exert an ameliorating
effect on arthritis progression and joint destruction when
given in combination with an antibiotic.
Treatment with PBN alone had no beneficial effect on
disease. Indeed, there was a tendency towards increased
mortality in animals receiving PBN from the first day of infec-
tion. Phagocytes manufacture large amounts of reactive oxi-
Figure 1
The effects of different treatment modalities on the prevalence and the
severity of septic arthritis. (a) The prevalence and (b) the severity of
septic arthritis in NMRI mice (n = 19–30) on days 3 and 10 following
intravenous infection with S. aureus strain LS-1 were evaluated. To
evaluate the severity of arthritis, a system of clinical scoring (arthritic
index) was employed, where macroscopic inspection yielded a score
of 0 to 3 points for each limb. The total index was calculated by adding
the individual limb scores for each animal tested. Results are
expressed as the mean ± SEM. CLOX, cloxacillin; PBN, phenyl-N-tert-
butyl nitrone.
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Figure 2
The curative effects of different modalities to treat septic arthritis. The
cure rate is expressed as the difference in the severity of arthritis
between days 3 and 10 following S. aureus infection in NMRI mice
(n = 19–30). All treatments were initiated on day 3 following
intravenous inoculation of bacteria and continued until day 10. Positive
values indicate amelioration of arthritis and negative values indicate
increased severity of arthritis between days 3 and 10. Results are
expressed as the mean ± SEM. *P < 0.05; **P < 0.005. CLOX,
cloxacillin; PBN, phenyl-N-tert-butyl nitrone.
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ganisms [14]. PBN scavenges radicals and probably
decreases phagocyte bactericidal capacity, thereby increas-
ing the bacterial burden and contributing to sepsis-induced
mortality. On the other hand, the ability of PBN to spin trap
free radicals could have directly diminished joint tissue
damage. The role of oxygen-derived free radicals in inflam-
mation and tissue damage is well established [15]. Interest-
ingly, another nitrone, tempol, has been shown to have
beneficial effects on collagen-induced arthritis in rats [16].
PBN suppresses proinflammatory cytokine production
(e.g. interleukin-1 and tumor necrosis factor-α) by mono-
cytes  in vitro [17]. The involvement of proinflammatory
cytokines in the pathogenesis of S. aureus infection has
been previously established [18–22] Thus, both direct
and indirect effects of PBN on immune cells and on the
production of cytokines might have contributed to the
observed amelioration of arthritis.
Conclusions
This is the first infectious model of inflammatory disease in
which PBN has been tested as a potential therapeutic
agent. We have shown that systemic administration of
PBN concomitant to antibiotic therapy improves the cure
rate in S. aureus-induced arthritis. The pleiotropic effects
of PBN in modulating macrophage and neutrophil activi-
ties within the joint may reduce destructive arthritis. There-
fore, PBN might have therapeutic applications to
nonseptic as well as septic inflammatory disease.
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